Key facts
- Medicare's GLP-1 Bridge program launches July 1, 2026, and runs until December 31, 2027.
- Eligible beneficiaries can access GLP-1 medications for weight management with a $50 monthly copay.
- The program requires a prior authorization request and prescription from a medical provider.
- Eligibility is based on BMI (27 or higher) and specific co-existing health conditions.
- The program operates outside the standard Medicare Part D coverage for weight loss drugs.
Starting July 1, 2026, Medicare beneficiaries will have access to GLP-1 medications for weight management through a temporary demonstration program known as the Medicare GLP-1 Bridge. This initiative, set to run until December 31, 2027, allows eligible individuals to obtain these drugs for a flat monthly copay of $50. The program is designed for beneficiaries who do not have a medically covered indication for GLP-1s through standard Part D coverage, as federal law currently prohibits Medicare from covering weight loss medications.
The Bridge program requires a prior authorization request and prescription from a medical provider. Eligible medications include Wegovy, Zepbound, and Foundayo. To qualify, beneficiaries must be at least 18 years old with a BMI of 27 or higher, along with specific co-existing conditions that vary based on BMI. Those with a BMI of 35 or greater do not need an additional diagnosis.
While praised by obesity advocacy groups as a significant step, regulatory observers have raised concerns about the program's administration, potential for fraud, and its overall cost, which CMS has not yet publicly disclosed. The program operates outside the typical Medicare Part D benefit structure, meaning the $50 copay does not count towards deductibles or out-of-pocket maximums. CMS has stated that more information regarding the program's future after 2027 will be shared later.